ONE SUBSTANCE-ONE REGISTRATION
46. Currently the Proposals encourage the formation
of consortia, but this is not mandatory. The UK Government is
presenting the case strongly for one substance-one Registration,
which would require the compulsory sharing of data. The Government's
proposals are set out in its consultation published in March 2004.
The advantages, it argues, are:[54]
- Minimising animal testing through sharing of
data in consortia;
- Reducing the cost of REACH to the economy by
sharing costs of testing;
- Maximising the sharing of existing data and creating
one data package per substance;
- Reducing the workload and simplifying the system
for industry and Authorities;
- Aiding rapid decision making through the use
of one registered data package; and
- Creating a level playing field for all registrants,
including late entrants to the EU market.
47. A key element of the Government's proposals is
a single pre-Registration phase, supported by the Substance Information
Exchange Forum and run by the ECA. This would make possible the
mandatory formation of consortia for joint Registration of chemicals.[55]
Few would argue with the Government's aims. The CIA has produced
a detailed critique of the workability of the proposals, particularly
relating to the compulsory formation of consortia.[56]
The Government itself recognises that several issues need to be
resolved for one substance-one Registration to be workable:
- Identity of the substance;
- Cost-sharing;
- Timing;
- Access to consortia;
- New substances introduced after the phase-in
process of Registration; and
- Commercial sensitivity.
48. The Government's proposals
address the identity of a chemical but, as the CIA sets out, the
situation is complicated by different companies producing the
same substance to different levels of purity. The impurities will
also differ according to the production process. The CIA points
out that an impurity profile would indicate the process used and
might reveal company secrets.[57]
We also understand that there are some very similar chemicals
with different uses which have the same CAS number.
Consortia
49. The Government argues that "in the interests
of fair and open competition, companies must be able to join consortia".
It suggests that industry should propose equitable cost sharing
guidelines detailing the data sharing and charging requirements
for late entrants. The issue of late joiners and free riders is
of concern to industry when costs have been incurred, the outcome
is known and the Registration has succeeded. [58]
The CIA reports that late joiners to consortia of this kind are,
on top of a share of the costs, charged a risk premium of 20-25%
and interest. This is complicated by the fact that completed studies
are a depreciating asset and that in theory a discount rate should
be imposed. A further issue is the membership of consortia of
organisation from different sectors with chemicals used for different
purposes and in very different volumes.[59]
The CIA points out that smaller producers will be disadvantaged
as they would be forced to register earlier under the volume thresholds
for Registration or pay consortia costs later even though they
possess much of the Registration data already. This problem could
be overcome by the introduction of a single pre-Registration deadline
soon after the Regulation comes into force.[60]
A further concern is that consortia tend to move more slowly than
single companies.[61]
However, the CBI concludes that the Government's proposal has
many attractions, provided that the competition and confidentiality
aspects can be managed and there is the flexibility for companies
to operate outside consortia.[62]
While we do not doubt the problems of late joiners and free
riders on consortia formation, we consider that having identified
the problems it should be possible to develop an equitable pricing
formula.
50. The CIA questions the legality of DEFRA's suggestion
that industry should not be made responsible for preparing guidelines
for cost sharing. This issue needs to be resolved but we suspect
that industry would rather draw up its own guidelines than have
them forced upon them by the Commission or an ombudsman. The CBI
expresses concern that some of the information required by REACH
is "extremely commercially sensitive" and that competition
law prevents companies from exchanging this information with others
directly. It argues that further thought needs to be given to
this issue with data held in a secure system and that company
names should not be associated with some information.[63]
51. Mr John Kemp, Corporate Health, Safety and Environment
Manager at Infineum International Limited, identified a further
issue. He felt that it was important to distinguish between the
generation of the physicochemical data and the data from animal
testing; and information about end uses and the risks associated
with end uses. He argued that for the first part, data-sharing
should be maximised, but that the same chemical can have very
different end uses and that trying to put all these factors together
in one risk assessment would slow down the whole process and make
it unworkable.[64]
52. While the Government seems keen to make one substance-one
Registration a key element of its position, its enthusiasm is
not shared by Commissioner Liikanen, who agreed with the suggestion
that mandatory consortia formation, critical to ideas of one substance-one
Registration, was a "dead duck".[65]
Mr Michael responded that "One has to ask what he meant by
that and what was meant by the question".[66]
We see little scope for interpretation in Commissioner Liikanen's
comments and are concerned that the Government's negotiating position
could be undermined if it continues to take this stance. There
is much to be gained from the promotion of one substance-one Registration.
While the legislation could do more to provide incentives and
encouragement to form consortia so that data sharing becomes the
norm but not the rule, the mandatory formation of consortia is
not workable. We consider the Government's position on this issue
to be untenable.
Chemical Safety Reports and Safety
Data Sheets
53. A chemical safety assessment (CSA) must be conducted
and a chemical safety report completed for all substances produced
in quantities over 10 tonnes. Where a substance is identified
as dangerous the Chemical Safety Report (CSR) must also include
an exposure assessment and risk characterisation. The CBI is pleased
that the requirement to conduct a CSA has been removed in the
Proposals for substances produced in quantities of below 10 tonnes.
It would still like to see more streamlining of the requirements
of the CSA and CSR with current environmental and health and safety
regulation.[67]
54. Under the Proposals, manufacturers or importers
have to provide downstream users with a safety data sheet (SDS)
for the purposes of managing their risk when using the substance.
The SDS must be consistent with the CSA. The consultation text
had indicated that CSRs would be necessary and this move has been
welcomed by industry as reducing the burden on downstream users.[68]
The Government also welcomes the European Commission's proposal
to adopt the existing SDS mechanism to improve the communication
along the supply chain. WWF describes the uses of SDSs as "an
adequate way of passing information to downstream users".[69]
We agree that the use of safety data sheets to improve communication
down the supply chain is a useful introduction.
17 Articles 15 and 16 Back
18
Ev 94 Back
19
http://europa.eu.int Back
20
Ev 102; Q 13 Back
21
Ev 65 Back
22
DEFRA, UK Consultation paper on the New EU Chemicals Strategy
- REACH, March 2004, para 126 Back
23
Ev 88 Back
24
Qq 10-11 Back
25
Ev 92; DEFRA, UK Consultation paper on the New EU Chemicals Strategy
- REACH, March 2004, para 55 Back
26
Ev 67 Back
27
Ev 101 Back
28
Royal Commission on Environmental Pollution, 24th Report, Chemicals
in Products: Safeguarding the Environment and Human Health, Cm
5827, June 2003, para 3.206 Back
29
Ev 79 Back
30
Q 110 Back
31
Q 173 Back
32
Ev 64 Back
33
Ev 91 Back
34
www.ecetoc.org Back
35
Royal Commission on Environmental Pollution. 24th report, 2003,
paras 4.15-4.18; Ev 61 Back
36
Chemical Abstract Service, a division of the American Chemical
Society; www.cas.org Back
37
Ev 94 Back
38
DEFRA, UK Consultation paper on the New EU Chemicals Strategy
- REACH, March 2004, para 69 Back
39
Articles 21, 26 Back
40
DEFRA, UK Consultation paper on the New EU Chemicals Strategy
- REACH, March 2004, para 80 Back
41
Q 236 Back
42
Q 285 Back
43
Ev 85 Back
44
Ev 61 Back
45
Ev 78 Back
46
Ev 56 Back
47
Ev 86 Back
48
Q 95 Back
49
Q 238 Back
50
Combes R et al (2003) An Overall Strategy for the Testing of Chemicals
for Human Hazard and Risk Assessment under the EU REACH System,
Alternatives To Laboratory Animals vol 31, pp 7-19, Back
51
Ev 85 Back
52
Q 271 Back
53
The Organisation for Economic Co-operation and Development Principles
of Good Laboratory Practice set out managerial concepts covering
the organisation of test facilities and the conditions under which
pre-clinical safety studies are executed. Their purpose is to
ensure the generation of high quality and reliable test data (in
vitro and in vivo) related to the safety of chemicals and preparations
in the framework of the Mutual Acceptance of Data. Back
54
Ev 53 Back
55
This has been discussed above in paragraphs 33-40 in relation
to the introduction of a risk-based approach to Registration Back
56
Ev 69-71 Back
57
Ev 70 Back
58
Ev 69-70 Back
59
Ev 70 Back
60
See paragraph 37-38 Back
61
Ev 71 Back
62
Ev 94 Back
63
Ev 92 Back
64
Q 234 Back
65
Q 197 Back
66
Q 282 Back
67
Ev 95 Back
68
Ev 95 Back
69
Ev 79 Back